Purpose Few prospective studies have reported on relationships between objective periodontal disease (PD) measures and cancer risk. This association was examined in 1,337 postmenopausal women participating in the Buffalo OsteoPerio Study. Methods Oral alveolar crestal height (ACH) was measured using oral radiographs. Incident cancers were adjudicated with medical records. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for associations between ACH and incident cancer outcomes were estimated using Cox proportional hazards models. Results There were 203 confirmed total incident cancer cases during follow-up (12.2 ± 4.2 years). After adjusting for age and smoking, there were no statistically significant associations between ACH-defined PD categories and total cancer risk (mild/moderate vs. none: HR 1.33, 95 % CI 0.91-1.94; severe vs. none: HR 1.20, 95 % CI 0.77-1.86). ACH-defined PD categories were not associated with common site-specific cancers. Whole-mouth mean and worst-site ACH (per 1 mm loss) were significantly associated with increased risk of lung (adjusted HR 1.81, 95 % CI 1.30-2.54; adjusted HR 1.34, 95 % CI 1.08-1.66, respectively), but not total or other site-specific cancer. Smoking status modified the associations between continuous ACH variables and total cancer risk; measures of PD were associated with total cancer among smokers but not never smokers (interaction p = 0.02 and p \ 0.01 for whole-mouth mean and worst-site ACH, respectively). Conclusions ACH-defined PD was associated with total cancer risk in ever but not never smoking postmenopausal women. Whole-mouth mean and worst-site ACH were associated with increased lung cancer risk. However, these results need to be interpreted cautiously given the small number of lung cancer cases (n = 18). Further research utilizing a larger sample is warranted to confirm the relationships among oral bone loss, site-specific cancers, and total cancer.
Introduction
Periodontal disease (PD) is characterized by chronic polymicrobial infection and inflammation of the gingiva that result in loss of connective tissue and alveolar bone surrounding the teeth [1] . PD is common in the elderly. Prevalence of PD was 70.1 % in US adults over age 65 examined in the 2009-2010 National Health and Nutrition Examination Survey (NHANES) [2] .
PD has been associated with increased risk of systemic illnesses, including cardiovascular disease, diabetes mellitus, respiratory disease, and rheumatoid arthritis [3, 4] . A potential mechanism is that PD promotes systemic inflammation via translocation of oral bacteria, bacterial toxins, and inflammatory mediators through frequent transient bacteremia [5] . Notably, heighted inflammation is known to promote carcinogenesis [6] . In addition, research suggests that oral bacteria could exert direct genotoxic effects on host cells or disrupt regulation of cell proliferation and survival pathways, facilitating malignant initiation as well as progression [7, 8] . Epidemiologic studies have shown that PD may be positively associated with cancers of the head and neck [9, 10] , pancreas [11] , colorectum [12] , lung [13] , and breast [14] . Three prospective cohort studies have indicated that PD increases risk of total cancer as well as of certain site-specific cancers [15] [16] [17] . Additionally, greater number of tooth loss was associated with higher risk of esophageal [18, 19] , gastric [18, 20] , and lung cancer [19] . However, the majority of these studies assessed PD using self-report or used tooth loss as a proxy for PD and were thus susceptible to misclassification bias.
Research utilizing valid and reliable measures to assess PD with use of those measures to determine the relationship between PD and cancer risk is needed. In the current study, we examined associations between measured alveolar crestal height (ACH)-an objective clinical index of PD severity-and cancer incidence among 1,337 postmenopausal women who participated in the Buffalo Osteoporosis and Periodontal Disease (OsteoPerio) Study, a prospective ancillary study of the Women's Health Initiative in Buffalo, New York.
Methods

Study population
Participants were postmenopausal women between 53 and 85 years of age enrolled in the Buffalo OsteoPerio Study, which was originally designed to investigate the role of osteoporosis in oral bone loss and periodontal disease. Details regarding enrollment of WHI as well as of OsteoPerio participants have been previously described [21, 22] . Between 1997 and 2000, a total of 2,249 postmenopausal women were recruited from the WHI Observational Study at the Buffalo Clinical Center. Of these individuals, 1,359 women met all eligibility criteria and completed the OsteoPerio Study baseline visit. For these analyses, we further excluded women who failed to complete and return all study questionnaires (n = 6) or had inadequate oral radiographs for ACH measurement (n = 16), resulting in an analytic sample of 1,337 women (Fig. 1) . This study was reviewed and approved by the University at Buffalo Institutional Review Board. Written informed consent was obtained from all participants.
Measurement of alveolar crestal height
ACH is a clinical measure of cumulative history of PD that reflects alveolar bone loss resulting from long-term iterative interactions between gingival bacterial infection and the host immune response. PD severity was determined by ACH measured during standardized oral examination at baseline. ACH is the distance from the cemento-enamel junction to the most coronal portion of the alveolar crest in a plane parallel to the long axis of the tooth [22, 23] . This measurement was recorded at mesial and distal sites of all teeth except for third molars and canines (maximum 24 teeth). Intra-oral radiographs were taken using a high-frequency X-ray generator equipped with an adjustable anode tube head adapted specifically for the OsteoPerio Study (Bennett HFQ 300 highfrequency X-ray generator, Bennett X-ray Corp., Copiague, NY). During imaging, participants were positioned to maintain a constant 18°angle between the midsagittal plane of the head and the tube head of the radiographic unit. Exposure time ranged between 0.1 and 0.45 s; images were captured at 65 kVP, 150 m Amp at a focus-to-film distance of 150 cm. All radiographs were developed using an automatic processor (Dent-X, Inc., Elmsford, NY) immediately after exposure and were then captured by a digital imaging system (Coreco F64PPRO DSP) for measurement. This imaging system was developed and validated by Hausmann and colleagues [23] [24] [25] . Intra-examiner and inter-examiner variability was 0.27 mm (mean SD) and 0.42 mm (SD), respectively, for repeated measures [23] .
Ascertainment of cancer end points
Participants were followed from the beginning of the study (1997-2000) through 30 September 2014. Cancer cases excluding non-melanoma skin cancers were identified from annual health updates in the WHI-OS and were adjudicated by trained physicians using medical records [26] . Nonmelanoma skin cancers were excluded because these types of cancer are relatively common, are often curable via surgical excision, and are associated with low mortality. Death certificates were used for adjudication when no medical records were available. For analyses of total cancer risk, time-to-event was defined as the interval between dates of enrollment and diagnosis of the first primary cancer at any location. For analysis of site-specific cancer risk, time-to-event was defined as the interval between dates of enrollment and diagnosis of the first primary invasive cancer at that location.
Assessment of other variables
Participants also completed at baseline a physical examination and questionnaires regarding their medical history, health behaviors, and medication use. Variables assessed as potential confounders include age at visit, race (white/ other), highest level of education (high school/college/postcollege), smoking history, secondhand smoke exposure (never/ever), alcohol consumption (ounces/day), physical activity [total metabolic equivalent task (MET) hours/ week], total energy intake (kcal/day), fruit and vegetables intake (servings/day), red meat intake (servings/day), caffeine intake (mg/day), lactose intake (g/day), hormone use (estrogen plus progesterone; never/former/current), current regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) (yes/no), current dietary supplement use (any vitamin, calcium, and vitamin D; yes/no), history of diagnosis of diabetes (yes/no), dental hygiene (frequency of toothbrushing, tooth flossing, and dental visits), family history of cancer (yes/no), age at menopause, age at menarche (B9-11/12-13/C14), parity (never pregnant or never had term pregnancy/1-2/3-4/C5), and use of oral contraceptives (never/ever). Body mass index (BMI; kg/ m 2 ) was calculated using measured height and weight and was further categorized as under-or normal weight (\25.0), overweight (25.0-29.9) , and obese (C30.0) according to WHO criteria [27] . Information on smoking history included smoking status (never/former/current), packs smoked per day, age at smoking initiation, and age at smoking cessation. Pack-years of smoking was computed by multiplying packs smoked per day by number of years smoked.
Statistical analysis
Comparisons of characteristics between women with incident cancer and the cancer-free participants were performed using Chi-square tests or Fisher's exact tests for categorical variables and independent t tests or Wilcoxon tests for continuous variables. Comparisons of characteristics across ACH-defined PD severity categories were performed using Chi-square tests or Fisher's exact tests for categorical variables and analysis of variance (ANOVA) or Kruskal-Wallis tests for continuous variables. Follow-up time for each participant was calculated from the date of the OsteoPerio Study baseline visit to the date of cancer diagnosis, death from any reason, loss to follow-up, or the end of the follow-up.
Cox proportional hazards regression was used to evaluate the associations among PD severity (defined categorically and continuously using whole-mouth mean and worst-site ACH), risk of total cancer, and risk of common site-specific cancers with more than 10 incident cases (i.e., breast, lung, colorectal, endometrial, hematological cancers, and melanoma). For ACH-defined PD category, participants were classified as having severe PD if they had whole-mouth mean ACH C 3 mm, or at least two-site ACH C 5 mm, or tooth loss due to PD; as having mild/moderate PD if they had whole-mouth mean ACH C2 to \3 mm, or at least one-site ACH C 4 mm, and no tooth loss due to PD; or as having no PD if they had wholemouth mean ACH \ 2 mm, no-sites ACH C 4 mm, and no tooth loss due to PD [22] . This operational definition incorporated self-reported tooth loss due to PD because ACH would be unobtainable at a particular site after tooth extraction. We further categorized PD status as any PD (mild/moderate/severe ACH loss) or no PD (no ACH loss). Moreover, we analyzed ACH as a continuous variable (mm) to maximize statistical power for both whole-mouth mean loss and worst-site of loss. Hazard ratios (HRs) and 95 % confidence intervals (CIs) of the associations were estimated in crude, age-adjusted, and multivariable-adjusted models. Potential confounding variables were selected on the basis of their associations with PD, total cancer, and common site-specific cancers, as well as biologic plausibility. We assessed for the potential confounding effects of age, BMI, education, smoking, secondhand smoke exposure, family history of cancer, combined hormone use, and frequency of tooth flossing on the associations among ACH-defined periodontal disease categories, total cancer, and the most common site-specific cancers. For colorectal cancer, we additionally assessed for the effects of alcohol consumption, physical activity, NSAIDs use, history of diabetes, and dietary variables (i.e., total energy intake, red meat intake, fruits and vegetables intake, lactose intake, calcium intake, and vitamin D intake). For breast cancer and endometrial cancer, we additionally assessed for the effects of physical activity, alcohol consumption, age at menopause, age at menarche, parity, and use of oral contraceptives. Since age is a wellestablished risk factor for many different types of cancer, we included it in all multivariable-adjusted models. Confounders were included in all multivariable-adjusted models if the addition of them, one at a time, changed the ageadjusted HR by more than 10 % for total or site-specific cancer outcomes. A parsimonious model-building approach was used to maximize statistical power and minimize potential selection bias. Participants with missing confounding variables were excluded from multivariableadjusted models. Effect modification by smoking status (never/ever smokers) was tested by adding an interaction term (smoking status 9 ACH) to the multivariable-adjusted model. A two-sided p value of 0.05 was used to evaluate statistical significance. All data analysis was performed using SAS 9.3 (SAS Institute, Cary, NC).
Results
After an average 12.2 (±4.2) years of follow-up, there were 203 incident cancer cases. Common site-specific cancers with more than 10 cases included breast cancer (n = 89), hematological malignancies (n = 24), colorectal cancer (n = 19), lung cancer (n = 18), melanoma (n = 13), and endometrial cancer (n = 12). Participant baseline age ranged from 53 to 84 years. Most were white (97.4 %), and more than half of the women were overweight or obese (56.0 %). A small proportion was current smokers (3.3 %) or had been diagnosed with diabetes mellitus (5.0 %). Approximately 76 % of participants had some forms of PD, among whom two-thirds of the women had mild/moderate ACH loss. Participant characteristics by ACH-defined periodontal disease category are presented in Table 1 .
The associations among ACH-defined PD, total cancer, and the common site-specific cancers are presented in Table 2 . In crude models, mild/moderate PD was positively associated with total cancer risk (HR 1.49, 95 % CI 1.02-2.16), and a suggestive association was seen for severe PD and increased total cancer risk (HR 1.41, 95 % CI 0.93-2.15). These associations were attenuated and not statistically significant after adjusting for age at visit and pack-years of smoking (mild/moderate vs. none: HR 1.33, 95 % CI 0.91-1.94; severe vs. none: HR 1.20, 95 % CI 0.77-1.86). Although not statistically significant, there was suggestive evidence of increased risk of total cancer among individuals with any PD compared to those with no PD in the multivariable-adjusted model (HR 1.29, 95 % CI 0.89-1.87). Regarding site-specific cancers, severe ACH was significantly associated with lung cancer risk in both crude and age-adjusted models, but not when pack-years of smoking was added to the model. There were no statistically significant associations between ACH-defined PD severity categories and any site-specific cancers in multivariable-adjusted models. Further adjustment for BMI, education, secondhand smoke exposure, family history of cancer, physical activity, tooth flossing, total energy intake, and dietary factors (i.e., consumption of alcohol, red meat, fruit and vegetables, caffeine, and lactose) did not appreciably change the results (data not shown).
When analyzed as continuous variables in models adjusting for age at visit and pack-years of smoking, significantly increased lung cancer risk was seen for wholemouth mean ACH (per millimeter loss, HR 1.81, 95 % CI 1.30-2.54) and worst-site ACH (per millimeter loss, HR 1.34, 95 % CI 1.08-1.66). Neither ACH measure was statistically significantly associated with risk of total cancer or of breast, colorectal, endometrial, hematological cancer or melanoma (Table 3) . Due to the potential synergism that smoking and PD could have on cancer risk, we performed a stratified analysis of the association by smoking status (never vs. ever) ( Table 4 ). For women who were ever smokers, PD status, ACH categories, and continuous ACH variables were all statistically associated with total cancer risk in crude, ageadjusted, and multivariable-adjusted regression models. These associations were not observed among never smokers. Statistical tests of interaction indicated smoking status significantly modified the associations of wholemouth mean (p = 0.02) and worst-site ACH (p \ 0.01) with total cancer risk.
Discussion
To our knowledge, the present study is the first longitudinal investigation of the association between measured oral bone loss as an indicator of PD severity and total cancer risk in postmenopausal women. ACH measures as continuous variables were found to be positively associated with lung cancer risk after multivariable adjustment. The continuous measures of ACH were not associated with risk of total cancer or of other site-specific cancers. Stratified analyses revealed a significant interaction between continuous ACH measurements and smoking status on total cancer risk; PD and measures of ACH were significantly associated with total cancer among smokers but not among non-smokers. There were no statistically significant associations between ACH-defined PD severity categories and risk of total or other site-specific cancers. However, the numbers of cancers were small and limited the power of analyses.
There has been evidence of longitudinal positive associations between periodontal disease and risk of total and lung cancer [15] [16] [17] 28] . In NHANES I Epidemiologic Follow-up Study, PD (assessed by probing measures and tooth mobility) was shown to be related to increased total cancer risk (OR 1.55, 95 % CI 1.01-2.97) [15] . In addition, PD was associated with lung cancer risk after adjusting for [16] . In a Swedish study, PD determined by self-report of tooth mobility was found to be positively associated with risk of total cancer (HR 1.15, 95 % CI 1.01-1.32) [17] . Although smoking was adjusted in previous studies and our analyses, the observed association between PD and lung cancer could be partially explained by residual confounding of smoking, in that smoking is a strong confounding factor of this relationship. Measurements of PD have varied across studies, including tooth mobility/loss, self-reported PD history, probing pocket depth, and attachment loss. Few studies have examined cancer risk with PD severity assessed using clinically measured ACH [9, 10] . This difference in measurement makes comparisons across studies difficult. Using tooth loss as a proxy for PD could be misleading as people may lose teeth for other reasons, such as dental caries and trauma. Self-reported PD is prone to misclassification bias, especially among participants with mild PD [29, 30] and among those who infrequently see a dentist. Probing measures could vary with gingival inflammation and recession [31] , and could improve after periodontal treatment, thus not reflecting cumulative PD history which may be relevant to carcinogenesis. In contrast, ACH represents the irreversible loss of alveolar bone resulting from long-term exposure to PD by the way of subgingival bacterial infection and altered host immune response. Progression of ACH loss could be mitigated by conventional periodontal treatment, but the lost bone would not be significantly regained [10] . Therefore, ACH serves as an optimal measure in assessing the association between chronic PD and cancer risk, though it is not typically available in large epidemiologic studies.
Results from stratified analysis suggest that wholemouth mean and worst-site ACH were not associated with total cancer risk in never smokers but were associated with total cancer risk in ever smokers after controlling for age at visit and pack-years of smoking. Although the interaction between PD status and smoking status did not reach statistical significance, there appears to be a qualitative difference between the effects of PD status on total cancer risk in ever smokers compared with never smokers. Smoking has been shown to increase chronic inflammation [32] and may compromise the protective immune response to bacterial infection [33] . Moreover, several types of oral bacteria are capable of metabolizing components of tobacco smoke into carcinogens such as nitrosamines [34] . Thus, the present findings may reflect a synergistic effect of PD and smoking on cancer risk. However, an alternative explanation is that the significant associations observed in ever smokers may be due to the residual confounding by smoking, despite adjustment for pack-years of smoking in our study. Previous studies have found stronger associations of PD with lung cancer [13] and head and neck cancer [10] in former smokers than in current smokers. Our study lacks statistical power to investigate these differential associations since only 36 cancer-free participants and eight cancer patients were current smokers. Further research utilizing a larger study sample is needed to validate the modifying effect of smoking on the association between PD and cancer risk.
Our study had several limitations. Most importantly, there were relatively few cancer cases in this cohort, and therefore, the results should be interpreted with caution, particularly for site-specific cancers. Power calculations indicated that we had sufficient statistical power to detect an HR of 1.5 for total cancer for comparison of women with PD to those without. However, we may have had insufficient power to detect the possible associations between PD and risk of certain site-specific cancers. The power of our study for the stratified analyses for sitespecific cancers was also restricted by small cell sizes. Additionally, this cohort of postmenopausal women consisted of volunteers and may be more health conscious than the general population. In general, these women had healthier behaviors and lower prevalence of risk factors common to PD and cancer including smoking, obesity, and diabetes. Therefore, the generalizability of our results may be somewhat limited. However, the potential influences of these risk factors on the association of interest were minimized. Furthermore, the definition of ACH-defined PD was partially based on self-reported tooth loss due to PD. A validation study comparing the reasons for tooth loss obtained from self-reports with dental records conducted in a subset of the OsteoPerio cohort found that women tended to underreport PD as the reason for their tooth loss [35] . Therefore, women with severe ACH might be mistakenly classified into the mild/moderate category, which may explain the observed lower increase in total cancer risk in individuals with severe ACH loss compared to individuals with mild/moderate ACH loss. Strengths of the study included the prospective design, allowing for demonstration of the temporality of the association of interest. In addition, each participant underwent a detailed oral examination with assessment of ACH conducted according to rigorous standardized protocols by trained dental examiners. Information on baseline characteristics related to both PD and cancer was extensively collected, allowing adjustment for potential confounding variables. Furthermore, cancer cases were adjudicated by trained physicians using medical records, which reduced the likelihood of outcome misclassification.
Conclusions
In this sample of postmenopausal women, there were no statistically significant associations between ACH-defined PD severity categories and risk of total cancer or of common site-specific cancers. Whole-mouth mean and worstsite ACH were statistically significantly associated with 
